Gilead Polymerase Inhibitor Demonstrates RVR In All ELECTRON Patients At Four Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
During its quarterly earnings call, Gilead gave the market a snippet of positive data for its hepatitis C candidate GS-7977, priming investors for the drug’s blockbuster potential.